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 regulatory T cells (Treg cells), which specifically 
express the forkhead family transcription factor Foxp3, are essential for the maintenance of 
immunological self-tolerance and immune homeostasis. Stimulation of the T cell antigen 
receptor (TCR) via recognizing self-peptide/MHC is required for their expression of Foxp3 in 
the course of their development in the thymus. The TCR repertoires displayed by Treg cells 
and naïve T cells are apparently distinct, suggesting that Treg cells with high reactivity to 
self-peptide/MHC ligands are somehow driven to Treg cell lineage in the thymus. Treg cells 
also require stimulation via TCR to exert suppression in the periphery. At the molecular level, 
assembly of Foxp3, Foxp3-interacting factors, and chromatin-remodeling factors, is in part 
under the control of TCR signaling, and TCR stimulation alters Foxp3-dependent 
transcriptional regulation, protein-protein interaction, and Foxp3 recruitment to the specific 
genomic loci. These findings collectively indicate that the TCR signaling is essential for 
suppressive function of Treg cells and that TCR has a determinant role for driving developing 






 Treg cell lineage and differentiation.  
 
 3 
1. Introduction  
 
A key feature of the immune system is its ability of self-nonself discrimination, 
which is required for eliminating invading pathogenic microbes while maintaining 
immunological tolerance to self-antigen. During thymic development of T cells, immature 
thymocytes express a highly diverse repertoire of  T-cell receptors (TCRs), including 
potentially harmful specificities for self-antigen. Self-reactive T cells produced in thymus are 
rendered self-tolerant by the mechanisms of central and peripheral tolerance. These cells are 
deleted in the thymus, and, when they have escaped the deletion, rendered anergic or 
suppressed by other T cells not to become activated or expand. Among these mechanisms of 
self-tolerance, accumulated evidence indicates that dominant suppression by regulatory T 
cells (Treg cells) is essential for establishing and sustaining self-tolerance and immune 
homeostasis.  
A direct demonstration of the role of immunosuppressive CD4
+
 T cells in 
self-tolerance is that depletion of a CD4
+
 subpopulation from normal rodents produces 
autoimmune disease and the reconstitution of the depleted population suppresses the disease 
development. Efforts to characterize such naturally present autoimmune-suppressive 
population by expression levels of cell surface molecules have revealed that it constitutively 




 T cells produces a 





 Treg population constitutes 5-10% of peripheral CD4
+
 T cells in 




Treg cells also provokes immune 
responses to commensal bacteria in the intestine, causing inflammatory bowel disease (IBD), 
and evokes immune responses beneficial to the host, for example, effective tumor immunity 




 Treg cells are 
expanded, they are able to suppress allergy, establish tolerance to organ grafts, prevent 







 Treg cells are capable of controlling a diverse variety of 
immune response whether it is physiological or pathological.  
In addition to characteristic expression of cell surface molecules such as CD25, 
natural Treg cells specifically express the transcription factor Foxp3. Foxp3 is a master 
control gene for Treg development since expression of Foxp3 in normal naïve T cells converts 
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them to Treg-like cells functionally and phenotypically. Genetic deficiency or dysfunction of 
Foxp3 is indeed causative of autoimmune disease such as type 1 diabetes, allergy, and 
immunopathology such as IBD in humans. Further, in the periphery, Foxp3
+
 Treg cells with 
similar immunological properties with thymus-derived Treg cells can be generated from naïve 
T cells under certain conditions.  
One of the key issues in current Treg cell research is to understand at the molecular 
level how Foxp3
+
 Treg cells are produced in the thymus and periphery and how they are 
capable of controlling such a variety of physiological and pathological immune responses 
against self and non-self. Obviously Foxp3
+
 Treg cells bear antigen specificity, which is 
essential for their development in the thymus and periphery. In addition, they need to be 
activated by antigen via TCR to exert suppressive activity. In this review, we first summarize 
immunological characteristics of Treg cells and then discuss how TCR signaling contributes 
to the development and function of Foxp3
+
 Treg cells. We also review how Foxp3 operates in 
Treg cells.  
 
2. Immunobiological characteristics of Treg cells 
(i) Foxp3 as a master regulator of Treg cell function 
Natural Treg cells specifically express Foxp3 [2-4]. The Foxp3 gene was first 
identified as a defective gene in the mouse strain Scurfy, which is an X-linked recessive 
mutant with lethality in hemizygous males and exhibit hyperactivation of CD4
+
 T cells and 
overproduction of proinflammatory cytokines [5]. In humans, mutations of Foxp3 result in 




 Treg cells, and thus cause the disease called 
immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome 
characterized by severe multi-organ autoimmune diseases, allergy, and IBD [6]. Foxp3 is 










 T cells 
in mice. It is a member of the forkhead/winged-helix family of transcription factors, 
containing a highly conserved C-terminal winged-helix/forkhead DNA-binding domain, a 
C2-H2 zinc finger, and a leucine zipper [7]. The N-terminal domain of Foxp3 is unique to the 
FOXP subfamily, and it is critical for transcriptional repression. Ectopic retroviral 









Treg-like cells that are able to suppress proliferation of other T cells in vitro and inhibit the 
development of autoimmune disease and IBD produced by Treg depletion [2, 3]. Foxp3 
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transduction in naïve T cells up-regulates the expression of CD25 and other Treg-associated 
cell-surface molecules, such as cytotoxic T lymphocyte-associated 4 (CTLA-4) and 
glucocorticoid-induced TNFR-related gene (GITR), and also represses the production of IL-2, 
interferon  (IFN-, and IL-4. These characteristics are closely similar to those observed in 
natural Tregs. Thus, Foxp3 is so far the most reliable Treg marker with functional relevance.  
 
(ii) Foxp3-dependent suppressive functions of Treg cells 
Many possible mechanisms for Treg-mediated suppression have been proposed in 
the past decade [8, 9]. The contribution of cell contact-dependent mechanisms is suggested by 
the in vitro inability of Tregs to suppress the proliferation of responder T cells when the two 
populations are separated by a semi-permeable membrane [10, 11]. Culture supernatant of 
antigen-stimulated Tregs also fails to exhibit suppressive activity. Following cell contact, Treg 
cells may kill responder T cells by a granzyme-dependent or perforin-dependent mechanism 
or deliver a negative signal to responder T cells leading to inhibition of T cell proliferation 
[12-14]. In addition, there is a possibility that IL-2 nonproduction by Foxp3
+
 Treg cells, 
together with their constitutive high expression of the high-affinity IL-2 receptor (IL-2R), 
makes Treg cells efficiently absorb IL-2 from the vicinity, thereby contributing to the 
hindrance of the activation/expansion of responder T cells [15]. Modification of APC function 
is also involved in the suppressive mechanisms. Activated Treg cells may down-modulate the 
expression of CD80 and CD86 on APCs, as well as stimulate DCs to express the enzyme 
indoleamine 2,3-dioxygenase (IDO) [16, 17]. IDO catabolizes conversion of the essential 
amino acid tryptophan to kynurenine, which is toxic to T cells neighboring the DCs. These 
processes appear to be dependent on CTLA-4 molecules expressed on the Treg cell surface. 
Activated Tregs can also kill APCs [18].  
In addition, Treg-mediated suppression involves secretion of suppressive humoral 
factors, such as IL-10, transforming growth factor- (TGF-), IL-35 and galectin-1 [8, 19, 20]. 
Although TGF- and IL-10 are not required for Treg-mediated suppression in vitro, they 
contribute, at least in part, to in vivo suppression of IBD induced in mice by Treg depletion 
[21, 22]. Furthermore, Treg cells, but not conventional T cells, secrete a novel inhibitory 
cytokine, IL-35, which is a member of the IL-12 family and a hetrodimer comprised of Ebi3 
and Il12/p35 [23]. IL-35 production in Treg cells is substantially increased after the 
co-culture with effector T cells, and required for maximal Treg function in vitro and in vivo.  
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Taken together, these in vivo and in vitro findings indicate that multiple mechanisms 
including cell-contact and factor-mediated ones may operate in Treg-mediated suppression. It 
remains to be determined how each one contributes to in vivo suppression under different 
conditions and whether there is any core mechanism which is indispensable for sustaining 
self-tolerance and immune homeostasis [24]. In this regard, it is worth noting that the 
expression of Foxp3 can confer suppressive activity to non-Treg cells. Among the molecules 
discussed above, Foxp3 controls the expression of IL-2, CD25, and CTLA-4 by binding to 
their promoters. IL-2 or CD25 deficiency or Treg-specific CTLA-4 deficiency produces fatal 
autoimmunity/inflammation similar to the one observed in Foxp3 deficiency. Assuming that 
IL-2 and its signaling via IL-2R (CD25) are mainly required for Treg survival, a 
CTLA-4-dependent mechanism of suppression may constitute a core mechanism of 
suppression in vivo [25]. 
 





 Treg cells require antigen stimulation via TCR to exert Treg 
suppressive function in vitro. Once activated by a specific antigen, Treg cells exhibit 
antigen-nonspecific suppression on the activation and expansion of other T cells [10]. For 
example, Treg cells specific for antigen A can be activated by an APC presenting antigen A; 
this antigen A-specific Treg cells can suppress the activation and expansion of not only 
antigen A-specific effector T cells but also antigen B-specific effector T cells recruited to the 
APC presenting both antigen A and B. That is, Treg cells are able to exert bystander 
suppression at least in vitro. Furthermore, with TCR transgenic mice, the concentration of 
antigenic peptide required to activate the peptide-specific Tregs to exert suppression in vitro is 
much lower (~100 times) than the concentration needed for activating naïve T cells with the 
same antigen specificity [10]. This high antigen sensitivity of natural Treg cells can mainly be 
attributed to their high expression of accessory molecules including adhesion molecules such 
as leukocyte function-associated molecule-1 (LFA-1) and intercellular adhesion molecule-1 
(ICAM-1), and also their “antigen-primed” or “semi-activated” state as suggested by high 
expression of CD44, CD25, GITR, folate receptor 4 (FR4), and CTLA-4 [26-28]. Indeed, in 
the presence of specific antigen, Treg cells outcompete with naïve T cells in forming 
aggregates around antigen-presenting DCs [25, 29]. This aggregation does not occur in the 
absence of antigen. This means that self-antigen-specific natural Tregs can be activated even 
 7 
by B7-low immature DCs that are presenting a low amount of self-peptide (for example, 
derived from ingesting apoptotic cells), even if the amount of the antigen is not sufficient to 
activate naïve self-reactive T cells. This is a key property of natural Treg cells engaged in 
dominant self-tolerance.  
 
(iv) Cytokines: IL-2 for Treg survival and TGF- for their peripheral induction. 
The constitutive high-expression of CD25 is a key feature of Foxp3
+
 natural Treg 
cells [30]. In Treg cells, Foxp3 represses the transcription of Il2 and activates Cd25, making 
them highly dependent on exogenous IL-2 for their maintenance in the periphery [31]. 
Deficiency of IL-2, CD25, or CD122 produces fatal autoimmune/inflammatory disease, 
which is mainly due to defective survival of natural Treg cells [32]. In humans, CD25 
deficiency also exhibits severe autoimmunity and allergy resulting from deficiency or 
dysfunction of Foxp3
+
 Treg cells [33]. In the thymus, Treg development is hampered by IL-2 
deficiency especially when combined with deficiency of other c cytokines (e.g., IL-7 and 
IL-15) [34, 35]. In addition, IL-2 is required for sustained expression of Foxp3 and CD25 in 
natural Tregs and enhances their suppressive function, at least in vitro [34, 36]. Thus, Treg 
development and maintenance are highly dependent on IL-2 secreted by other subsets of 
lymphocytes, while Treg itself suppresses IL-2 production.  
Treg cells are generated in several experimental conditions, for example, by in vitro 
antigenic stimulation of naïve T cells in the presence of TGF- and IL-2 [37]. In this 
TGF--dependent Treg induction in vitro, IL-6 hampers the induction [38]. Interestingly, 
antigen stimulation in the presence of TGF- and IL-6 facilitates differentiation of naïve T 
cells to Th17 cells in mice [39, 40]. IL-2 on the other hand inhibits the differentiation [41]. 
These findings indicate that TCR stimulation in the presence of particular combinations of 
cytokine is able to drive naïve T cells to differentiate to Treg cells as well as a variety of 
helper T cell subsets including Th1, Th2, and Th17 cells. 
 
3. Cellular and molecular basis of Treg cell development and repertoire formation 
The immunological features of Foxp3
+
 Treg cells discussed above indicate that TCR 
signal, together with other signals including cytokine, is essential for their development in the 
thymus and periphery. TCR signal may also turn on the expression of Foxp3 in developing T 
cells in the thymus. 
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(i) Essential roles of TCR for Treg cell development 
The observation that Treg cells do not develop in TCR transgenic mice deficient 
in recombination activating gene (RAG
-/-
) strongly indicates that Treg cell development in the 
thymus requires TCR gene rearrangement at the TCR -chain locus and resulting TCR 
specificities different from the transgenic TCR specificity. The number of Foxp3
+
 Treg cells 
in TCR and TCR transgenic mice is substantially reduced, also suggesting that TCR 
specificity contributes to Treg cell development [26]. Moreover, a mutation in the gene 
encoding LAT (linker of activated T cell), a TCR proximal signal transduction molecule, 
abolishes the generation of Foxp3
+
 Tregs in the thymic and periphery while allowing the 
development of other T cells [42]. This indicates that Treg development requires a strong 
signal via the TCR in the thymus. Furthermore, in double-transgenic mice expressing a 
transgene-encoded peptide in the thymic stromal cells at a high level, the majority of T cells 
expressing transgenic  and  chains specific for the peptide differentiate to CD25+CD4+ T 
cells [43, 44]. A recent study also showed that inactivation of Lck, which blocks their capacity 
to signal through their TCRs, results in abnormal Treg homeostasis characterized by impaired 
turnover, preferential redistribution to the lymph nodes, and loss of suppressive function [45]. 
Altogether, these studies indicate that the TCR signaling is essential for the development of 
natural Treg cells in the thymus and their various functions including migration and 
suppression. 
In addition to the signaling via TCR, costimulatory signal is required for the control 
of Treg development and homeostasis. For example, CD28-deficient mice develop a reduced 
number of Foxp3
+
 Treg cells [46]. Mice deficient in CD28 or B7-1/B7-2 on 
non-autoimmune-prone backgrounds display profoundly defective immune responses; 
however, CD28 or B7-1/B7-2 deficient mice on the diabetes-prone NOD background develop 
a fulminant form of diabetes [47, 48]. Exacerbation of the disease is accompanied by a 




 Treg cells in these mice. Furthermore, the 
occurrence of diabetes can be suppressed in NOD-CD28 deficient mice by injection of 
wild-type Treg cells [49]. These findings indicate that CD28-B7 interaction is critical for 
thymic generation and peripheral maintenance of Treg cells. 
 
(ii) Requirement of thymic epithelial cells for Treg cell development 
Development of Treg cells relies not only on TCR signal, but also on signal from T 
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cell accessory molecules interacting with thymic stromal cells. Most of Foxp3
+
 thymocytes 
are found in the thymic medulla, indicating that the differentiation of developing T cells to 
express Foxp3 occurs in the thymic medulla. At the cellular level, both medullary thymic 
epithelial cells (mTECs) and DCs in the thymus contribute to Treg generation/differentiation. 
For example, deficiency in tumor necrosis factor receptor-associated factor 6 (TRAF6) or 
NF-kB-inducing kinase results in the absence of mature mTECs, hampering the development 
of Tregs [50, 51]. A population of mTECs ectopically expresses a set of tissue-specific 
antigens (TSAs), such as insulin, under the control of the Aire (autoimmune regulator) gene 
[52]. Interestingly, Aire-deficient mice spontaneously develop autoimmune diseases similar to 
those produced by Treg depletion, although Aire-deficient mice bear a normal number and 
apparently normal function of Foxp3
+
 Treg cells. It remains obscure whether Aire-expressing 
mTECs contribute to the formation of TCR repertoire of Foxp3
+
 Treg cells reactive with 
TSAs.  
 
(iii) TCR repertoire formation in Foxp3
+
 Treg cells  
TCR repertoires of Foxp3
+
 Tregs and Foxp3
-
 conventional T cells are distinct with 
some overlaps as suggested by the following findings.  
In TCR  transgenic mice, which spontaneously develop CD25+CD4+ Treg cells 
as in nontransgenic mice, Treg cells predominantly express endogenous TCR  chains paired 
with the transgenic  chain [26]. In contrast, the majority of CD25-CD4+ T cells express the 
TCR solely composed of transgenic  and  chains. RAG deficiency in these TCR transgenic 





 Tregs, indicating that self-reactive TCRs utilizing endogenous  
chains contribute to positive selection of Foxp3
+
 thymocytes. Similarly, in a mouse 
experimental allergic encephalitis (EAE) model, mice expressing an encephalatogenic TCR as 
a transgene are protected against the development of EAE when the mice are able to rearrange 
the endogenous TCR gene. However, these TCR transgenic mice with RAG deficiency 






 Treg cells only 
develop among T cells that express endogenous TCR chains in addition to the transgenic TCR 
[53]. In these studies, restricting CD4
+
 T cells to solely express the transgenic TCR inhibits 
the formation of an effective Treg repertoire, allowing CD4
+
 T cells expressing the transgenic 
TCR to induce disease.  
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The diversity of TCRs displayed by Treg cells versus non-Treg cells has been 
assessed by sequencing V2-containing variable regions of the TCR -chain (TCR) from T 
cells purified from mice expressing a TCR transgene and a single copy of the TCR locus 
(Tcra
+/-







 T cell subsets are comparable, but the repertoires are 





 conventional T cells, indicating that a subset of thymocytes with distinct TCR 
sequences is recruited to the Treg lineage during thymic development. 
Additionally, a recent report has suggested the presence of two subsets of peripheral 
Foxp3
+
 Treg cells differing in the level of Foxp3 expression and the TCR repertoire [56]. Treg 
cells expressing a high level of Foxp3 and TCRs not used by naïve CD4
+
 T cells exhibit a 
stable suppressor phenotype and dominate the peripheral Treg population. The second Treg 
subset, expressing a lower level of Foxp3 and using TCRs shared with naïve CD4
+
 T cells, 
constitute a small fraction of Treg cells and have a versatile phenotype and may 
down-regulate Foxp3 expression. Thus, there appears to be a correlation between the level of 
Foxp3 expression and functional stability of Treg cells. 
Based on these observations, it is likely that TCR engagement by a high-affinity 
self-ligand initiates signaling cascades that induce Foxp3 expression, which further drives 
thymocytes to the Treg cell lineage. Furthermore, several lines of evidence indicate that the 
availability of a “niche” for cognate antigen is important for the decision of Treg cell fate, 
generation or elimination in thymus [57, 58]. The precise mechanism of this selection and 
differentiation of Foxp3
+
 Treg cells and stable maintenance of Foxp3 expression in Treg cells 
remain to be elucidated.  
 
(iv) Another master for Treg cell development? 
Although Foxp3 is recognized as the master of Treg development, recent studies 
suggest that Foxp3 is not required for the initial commitment of Treg cell lineage in the 
thymus. Using reporter mice in which the Foxp3 coding region is replaced by a green 
fluorescent protein (GFP) reporter, two groups have demonstrated that GFP-positive 
thymocytes, which do not express the Foxp3 protein, show some characteristics of the Treg 
phenotype including the expression of CD25, GITR and CTLA-4, although they are not 
suppressive in vitro [59, 60]. This indicates that thymocytes are driven to the Treg lineage 
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without Foxp3, and that once the Foxp3 gene is transcribed, Foxp3 may stabilize and sustain 
the Treg phenotype and confer suppressive activity. In addition, insulin-like 7, galectin-1, 
granzyme B and helios genes are found to be specifically expressed in natural Treg, but 
independent of Foxp3 expression; for example, ectopic Foxp3 expression in conventional 
naïve T cells fails to up- or down-regulate the expression of these genes in contrast with 
Foxp3-controlled CD25, CTLA-4, GITR and other genes [59, 61, 62]. Furthermore, a 
cross-sectional analysis of the Treg cell signature in Treg-like cells generated under a number 
of conditions with or without Foxp3 has revealed that much of the Treg cell signature is not 
ascribable to Foxp3 [62]. These findings indicate that a higher level of regulation, which is 
independent of Foxp3, might exist in the Treg lineage commitment. Thus, it is intriguing to 
determine what mechanisms define the Treg differentiation program and turn on Foxp3 gene 
expression in developing thymocytes.  
  
4. Molecular basis of Foxp3 induction and function 
(i) Factors required for Foxp3 induction 
Foxp3 induction in Treg cells is controlled via a variety of signaling pathways 
involving TCR, IL-2, signal transducers and activators of transcription (STAT), Smad, TGF-, 
phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR, and Notch. Upon TCR engagement with 
self-peptide/MHC ligands, Foxp3 expression is controlled by transcription factors that can 
bind to the promoter or enhancer regions of the Foxp3 gene. Within the 5’ flanking region of 
the Foxp3 transcription start site, there are several important transcription factor-binding sites, 
including those for AP-1 and NFAT, along with typical sites of eukaryotic promoters 
including TATA and CAAT boxes. This region acts as the promoter for Foxp3 transcription 
and is referred to as the proximal promoter region, which is highly conserved over many 
species. Recent studies have shown that these NFAT and AP-1 binding sites positively 
regulate the transcriptional activation of the Foxp3 gene in response to TCR stimulation. 
NFAT and Smad3 binding sites also locate in an enhancer region of the Foxp3 gene [63]. 







Treg cells and is also induced by TGF- coupled with anti-CD3 and anti-CD28 stimulation in 
primary CD4
+
 T cells. NFAT and Smad3 cooperate to induce Foxp3 gene expression and 
NFAT maintains activity of the enhancer and consequently Foxp3 gene expression. Further, 
induction of Foxp3 expression is blocked by the Smad3 inhibitor SIS3 [63]. Thus, NFAT and 
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Smad3 are key transcription factors that induce the expression of the Foxp3 gene and govern 




 Treg cells.  
Moreover, a TCR-responsive enhancer found in the Foxp3 first intron contains 
cyclic-AMP response element binding protein (CREB)/activating transcription factor (ATF) 
site overlapping a CpG island [64]. Methylation of this island inversely correlates with CREB 
binding and Foxp3 expression. TGF-, which induces Foxp3+ Treg cells from naïve CD4+ T 
cells, decreases methylation of the CpG island and increases Foxp3 expression. A 
dominant-negative CREB construct that can inhibit not only CREB but also ATF1 and ATF2 
diminishes PMA/ionomycin induced Foxp3 expression in a dose-responsive manner when a 
Foxp3 first intron-containing construct is used in reporter assay [64]. Thus, TCR-induced 
Foxp3 expression in Treg cells is controlled both by sequence-specific binding of CREB/ATF 
and by DNA demethylation of a CpG island. 
Besides TCR signaling, a variety of signaling pathways controls the expression of 
Foxp3. One of them is signaling from IL-2 via the IL-2 receptor. This signaling is generally 
dependent on STAT5. Consensus sites for STAT5 binding are found in the proximal promoter 
and intronic regions of Foxp3. However, only the proximal promoter conserved region shows 
binding with STAT5, dependent on IL-2R signaling.  
The vitamin A metabolite retinoic acid (RA) also induces de novo generation of 
Foxp3
+ 
Treg cells. In the presence of TGF-, RA facilitates the differentiation of naïve T cells 
to Foxp3
+
 Treg cells [65-67]; and all-trans-retinoic-acid induces histone H4 acetylation at the 
Foxp3 locus. However, there is no report showing that activated RA receptor directly control 
the expression of Foxp3. Thus far, RA induction of Treg cells from naïve CD4
+
 T cells can be 
attributed to enhanced TGF- driven phosphorylation of SMAD3 along with the inhibition of 
IL-6 and IL-23 receptor expression [68].  
Together, these findings indicate that several diverse intrinsic and extrinsic signals 
regulate Foxp3 expression, and that TCR signaling can be a critical factor for Foxp3 
induction.   
 
(ii) Foxp3-dependent control of Treg function 
Through genome-wide analysis combining chromatin immunoprecipitation with 
DNA microarray, Foxp3 binds to the regions for ~700 genes, and a large number of 
Foxp3-bound genes are up- or down-regulated in Foxp3
+
 cells [69]. The study suggests that 
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Foxp3 acts as both a transcriptional activator and repressor. In another study, Foxp3 binds to 
forkhead motifs of about 1,100 genes in PMA/inomycin stimulated T cell hybridomas [70]. 
Most of the promoters occupied by Foxp3 in stimulated T cells are also occupied in 
unstimulated cells. However, the intensity of Foxp3 binding considerably increases at some 
promoters upon PMA/ionomycin stimulation. These findings are in line with observations that 
suppressive function of Tregs requires TCR engagement. Foxp3 binding genes are enriched 
for the genes involved in signaling pathways, cell communication, and transcriptional 
regulation, including those encoding cell surface molecules (e.g. Il2ra, Ctla4, and FasL), 
TCR signaling-related molecules (e.g. Zap70 and Ptpn22), transcription factors (e.g. Foxp3 
itself), cytokines (e.g. Il2), enzymes for cell metabolism (e.g. Pde3b), and microRNAs (e.g. 
miR-155). Altogether, these genome-wide studies clearly show that Foxp3 controls a variety 
of physiological processes, and functions as an activator as well as a repressor of transcription 
depending on the target genes.   
Foxp3
+
 Treg can also functionally differentiate to acquire an ability to control Th1, 
Th2 or Th17 type immune responses. For example, a fraction of Foxp3
+
 natural Treg 
expresses the Th1-specifying transcription factor T-bet in response to IFN- [71]. They 
up-regulate CXCR3, a T-bet-controlled chemokine receptor, and then guide themselves to 
type 1 inflammation sites. In addition, Foxp3 directly controls the expression of the 
transcription factor interferon regulatory factor-4 (IRF-4), which is required for Th2 
differentiation [72]. Interestingly, Treg-specific deletion of IRF-4 impairs the control of Th2, 
but not Th1 immune responses, resulting in spontaneous development of Th2 type 
inflammation. Moreover, a recent study shows that Foxp3 is associated with the 
transcriptionally active, phosphorylated form of Stat3, which is a critical transcription factor 
for Th17 differentiation [73]. Stat3 activation-dependent association with Foxp3 
transcriptional complexes may result in modulation of Stat3-dependent gene expression in 
part through Stat3-dependent recruitment of Foxp3. Thus, the activation of Stat3 in Tregs 
endows them with the ability to suppress Th17 responses through increased expression of a 
subset of suppressor molecules as well as cytokine and chemokine receptors. In aggregates, 
Foxp3 modifies a transcriptional control of the lineage specific transcription factors and 
acquire an ability to control specific immune responses. Conversely, lineage specific 
transcription factors, such as T-bet, IRF-4 and Stat3, may facilitate Treg cell ability to 
suppress the corresponding type of the immune response. 
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(iii) Foxp3-interacting factors for the Foxp3-dependent transcription 
Foxp3-dependent transcriptional regulation also requires other transcription factors 
along with chromatin-remodeling factors, histone deacetylase, and histone acetyltransferase, 
to perform accurate transcriptional regulation in Tregs [74]. To examine the Foxp3-dependent 
regulation, attempts have been made to find the molecules associated with Foxp3. These 
studies have revealed that Foxp3 interacts with the transcription factor NFAT (nuclear factor 
of activated T cells), AML1 (acute myeloid leukemia-1)/Runx1 (runt-related transcription 
factor 1), RORt (RAR-related orphan receptor C) and Eos (Ikaros family zinc finger protein, 
subfamily 1A, member 4) [75-78]. Moreover, by MS/Qstar spectrometric analysis of the 
immunoprecipitated Foxp3 complex in ectopically Foxp3-expressing T cells, Foxp3 is shown 
to form a large transcriptional complex with several chromatin remodeling factors including 
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, 
member 4 (BRG1); Methyl-CpG binding domain protein 3 (MBD3); and RuvB-like DNA 
helicases TIP49a and TIP49b; and ATP-dependent DNA helicase II 70kDa subunit Ku70 [74]. 
Those chromatin remodeling factors co-fractionate precisely with Foxp3 in a large molecular 
weight complex. Transcriptional control exerted by Foxp3 also involves HATs, such as TIP60, 
and HDACs, such as HDAC7 and HDAC9. Acetylation of Foxp3 by TIP60 enhances the 
binding of Foxp3 to the Il2 promoter and augments the repression of Il2 [79]. 
Thus, transcription complex containing Foxp3 might be a key to address the 
complexity of the expression of Treg-associated molecules, suppressive functions, and 
stability of Treg lineage. In the following sections, we will focus on the transcription factors 
NFAT, Runx1, RORt and Eos, all of which are shown to interact with Foxp3, and appear to 
play specific roles for Treg cells.   
 
(a) NFAT 
The activity of NFAT is controlled by calcium and the calcium-dependent protein 
phosphatase calcineurin. In resting cells, these proteins are heavily phosphorylated and reside 
in the cytosol. TCR engagement results in the activation of the calmodulin-dependent 
phosphatase calcineurin, which binds to the N-terminus of NFAT and dephosphorylates 
multiple serine residues in the NFAT protein [80, 81]. After dephosphorylation, NFAT 
proteins translocate into the nucleus and initiate the transcription of NFAT-target genes [82]. 
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Activated NFAT forms a complex with AP-1 and NF-kB and promotes the expression of IL2, 
IL4, Ctla4, and other genes in conventional T cells [83]. Thus, NFAT contribute to the 
activation of T cells and their differentiation to effector T cells.  
A recent study has shown that Foxp3 can associate with NFAT, and the interaction 
between Foxp3 and NFAT is dependent upon their cooperative binding to DNA [75]. Crystal 
structure of a complex containing the forkhead domain of Foxp2 and the DNA binding 
domain of NFAT1, demonstrates that Foxp proteins can associate with NFAT transcription 
factors in the transcriptional complexes [84]. These complexes bind to NFAT:AP-1 composite 
sites on the IL-2 promoter and likely displace NFAT:AP1 complexes, thereby directly 
repressing IL-2 transcription. Amino acid substitutions of Foxp3 that disrupt the Foxp3-NFAT 
interaction impair the ability of Foxp3 to repress Il2, activate Ctla4 and Cd25, and confer 
suppressive activity [84]. Thus, the interaction between NFAT and Foxp3 is essential for the 
function of Foxp3. In fact, mice deficient in both NFATc2 and NFATc3 spontaneously develop 
severe lymphoadenopathy and selective activation of Th2 cells, suggesting that the deficiency 
might disrupt the function of Foxp3 and consequently impair Treg function [85].  
 
(b) Runx1  
Runx proteins are transcription factors that have crucial roles for the development 
of many tissues and the immune system, and form a family of evolutionarily conserved 
heterodimeric transcription factors [86]. Runx complexes are composed of unique 
DNA-binding -subunits, Runx1, Runx2, or Runx3, which are homologues of the Drosophila 
runt gene. To form the functional complexes, they pair with the non-DNA binding subunit 
core-binding factor , Cbf, which has been shown to stabilize the interaction of Runx 
proteins with DNA. Targeted deletion of Runx subunits has revealed that Runx family 
proteins possess distinct roles for development. For example, Runx1 deletion is shown to be 
required for haemotopoiesis [87], and Runx3 for neurogenesis [88].  
In naïve T cells, Runx1 constitutively binds to the Il2 promoter at the site upstream 
to the binding sites of NFAT and AP-1 [76]. Upon T cell activation, Runx1 may act as an 
organizing factor that facilitates the assembly of active transcriptional complex on the Il2 
promoter. On the other hand, in Treg cells, Runx1 has been shown to bind to Foxp3 at its 
N-terminal region in Tregs and play a role for Foxp3-mediated transcriptional regulation. 
Disrupting the binding between Foxp3 and Runx1 impairs the Foxp3-dependent suppression 
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of IL-2 production and attenuates suppressive activity. Knockdown of Runx1 in natural Tregs 
abrogates their suppressive activity. These results suggest that the interaction between Runx1 
and Foxp3 is essential for Treg function in vitro. Furthermore, Kitoh et al. have recently 
demonstrated that Treg-specific ablation of Cbf or Runx1, but not Runx3, causes 
autoimmune/inflammatory disease in mice [89]. Since the Cbf subunit acts as a binding 
partner for all Runx proteins, targeted inactivation of Cbf expression abrogates the activity 
of all Runx complexes [90, 91]. Treg-specific deficiency of Cbf induces lymphoproliferation, 
autoimmune disease, and hyperproduction of IgE. Similar Treg cell-specific gene targeting 
has revealed that the Runx and Cbf complex is required for the maintenance of Foxp3 
mRNA and protein expression in Treg cells [92]. Indeed, Foxp3 expression in natural Treg 
cells correlates well with the binding of Runx/Cbf to regulatory elements within the Foxp3 
locus. In addition, Cbf-deleted Treg cells exhibit impaired suppressive function in vitro and 
in vivo, with altered gene expression profiles including attenuated expression of Foxp3. 
Interestingly, Runx-binding site-dependent transactivation is observed only under activated 
condition, and not under unstimulated condition. These observations suggest that the Runx 
complex regulates constitutive Foxp3 expression rather than by transactivating the Foxp3 
gene. In addition, Runx promotes de novo expression of Foxp3 during inducible Treg cell 
differentiation in vitro, and a dominant-negative Runt DNA binding domain antagonized the 
de novo Foxp3 expression [93]. It has been shown that Runx1/Cbfb is not only a conventional 
transcriptional activator but also plays a critical role for properly guiding and forming 
Foxp3-containing transcriptional complex required for Foxp3-dependent transcription at 
specific DNA loci.   
In line with the possible contribution of Runx1 to the Foxp3-mediated Treg function, 
there are some reports indicating the importance of Runx family in autoimmunity. 
Runx3-deficinet mice spontaneously develop IBD and hyperplastic gastritis-like lesions, 
which are immunologically similar to those produced by Treg depletion [94, 95]. 
Disease-associated regulatory single nucleotide polymorphisms (SNPs) affecting the 
consensus sites for Runx1 are associated with genetic susceptibility to several autoimmune 
diseases including systemic lupus erythematosus, rheumatoid arthritis, and psoriasis [96-98]. 
In addition, a SNP in the Runx1 gene itself is strongly associated with rheumatoid arthritis 
[98]. It is thus likely that genetic anomalies of Runx family may contribute to the 
development of autoimmune disease and other immunological diseases by means of affecting 
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Treg-mediated immune regulation.  
 
(c) RORt  
Foxp3 also appear to interact with RORt, a key transcription factor for the 
differentiation of naïve T cells to Th17 cells characterized by the production of IL-17A, 
IL-17F, IL-21, and IL-22 [77]. Th17 cells play a key effector part in autoimmune diseases, 
elimination of extracellular bacteria, and cancer [99-101]. RORt-mediated IL-17A promoter 
activation is suppressed by forced expression of Foxp3, and Foxp3 directly interacts with 
RORt through exon2 region of Foxp3. Thus, the interaction between Foxp3 and RORt 
might be important for the suppression of Th17 and polarization into induced Tregs. While 
Th17 differentiation of naïve T cells is initiated by IL-6 and TGF-[39, 40, 102], TGF- also 
drives the conversion of naïve T cells to Foxp3
+
 Treg cells [103]. This suggests that the 
presence or absence of proinflammatory cytokines might lead to opposing immune 
consequences induced by TGF-, and the interaction between RORt and Foxp3 may be 
involved in the regulation of the Th17-Treg balance.  
 
(d) Eos  
One important feature of Treg cells is selective gene silencing of cytokine genes 
such as IL-2 and IFN-. It has been shown recently that Eos, a member of the Ikaros family, 
as a critical mediator of Foxp3-dependent gene silencing in Tregs [78]. The Ikaros family 
consists of zinc finger type transcription factors including Ikaros, Aiolos, Helios, and Eos. 
Some of them are expressed in lymphocytes and have been implicated in controlling 
lymphoid development. These proteins contain two characteristic clusters of zinc fingers, an 
N-terminal domain important for DNA recognition, and a C-terminal domain that mediates 
homo- and heterodimeric associations between family members. Eos can interact with Foxp3 
and induces chromatin modifications that result in gene silencing in Treg cells. Knockdown of 
Eos in Treg cells abrogates their ability to suppress immune responses, suggesting critical role 
of Eos in Treg programming. Interestingly, Eos is involved in the Foxp3-dependent gene 
repression, but not in the activation, suggesting that Foxp3 suppresses gene expression 
through its interaction with Eos. Eos also interacts with C-terminal binding protein-1 (CtBP1), 
which has been shown to suppress transcription by affecting histone methylation and 
acetylation [104]. Thus, CtBP1 is implicated as a key repressor of Eos-mediated gene 
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expression as a component of corepressor complexes, and the complexes containing Eos, 
CtBP1 and Foxp3 may control the epigenetic status of the Foxp3-target genes.  
  
(iv) Epigenetic control of Treg cells 
Treg cells show hypoproliferation upon TCR stimulation in vitro, whereas natural 
Treg cells are continuously proliferating in vivo presumably through recognition of 
self-antigen and commensal microbes [31, 105]. Compared to naïve T cells, Treg cells 
specifically and continuously express a set of genes, such as Il2ra (CD25), Ctla4 and Gitr. 
The permanent and heritable gene expression profiles of proliferating Treg cells may be 
maintained by epigenetic program.  
Molecular mechanisms of epigenetic programming include selective demethylation 
of CpG motifs and histone modifications. Complete demethylation of CpG motifs are found 











 T cells. Partial DNA demethylation is already found within developing 
Foxp3
+
 thymocytes; however, Tregs induced by TGF- in vitro display only incomplete 
demethylation [106]. It suggests that a more complete CpG demethylation may be required 
for a stable Foxp3 expression. In addition, naïve T cells in humans readily express Foxp3 
upon TCR stimulation, although the expression is generally much lower and more transient 
than in natural Tregs, suggesting that incomplete demethylation of the Foxp3 gene affects 
Foxp3 expression levels and its sustained expression. Consistent with these findings, 
demethylation induced by 5-azacytidine in human NK cells leads to induction of Foxp3 [107], 
and deficiency of DNA methyltransferase 1 (Dnmt1) induces enhancement of Foxp3 
expression [108]. Thus, constitutive expression of Foxp3 in natural Tregs is controlled by 
DNA methylation of CpG islands in the Foxp3 gene, and control of DNA methylation at the 
Foxp3 locus is essential for establishing Treg cell lineage.  
Apart from inheritance of methylated CpG residues in genomic DNA, parental 
histone molecules can also divide and be transmitted to the progeny cells. TCR stimulation 
induces H3-K4 di- and tri-methylation at the Foxp3 promoter and intronic enhancer regions 
after 18 hours of stimulation of naïve CD4
+
 T cells. This is in line with the observations that 
Foxp3 expression in CD4
+
 T cells is controlled by TCR signaling, and the Foxp3 promoter 
and enhancer are also H3-K4 methylated in Tregs. Therefore, the TCR stimulation may 
initially affect the histone code of the Foxp3 gene, thereby leading to the establishment of 
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epigenetic status of Treg cells.  
Moreover, demethylation of the Foxp3 promoter region and the CpG island in the 
enhancer is important for the induction of Foxp3. Demethylation of the regions is controlled, 
at least in part, by signaling from TGF- and TCR. The finding is in line with the observation 




 T cells by stimulation with 
TGF-, anti-CD3 and anti-CD28. A TGF- response element, however, has not been 
identified in the Foxp3 gene or in surrounding regions, suggesting that TGF- may modulate 
expression profiles of factors related to epigenetic control. The importance of TCR signaling 
in Foxp3 induction is also shown by using a genetic model of DNA methyltransferase 1 
(Dnmt1) deficiency. In Dnmt1 knockout mice, TCR stimulation can induce Foxp3 expression 
at a high level [108]. Moreover, in the absence of Dnmt1, Foxp3 induction in thymic and 
peripheral Foxp3-negative T cells is maximized upon TCR stimulation, and the provision of 
TGF- is dispensable for Foxp3 expression. These observations suggest that the TCR signal is 
sufficient for transcriptional activation of Foxp3 in the absence of maintenance DNA 
methylation. 
 
5. Concluding remarks 
Treg cells have been shown to suppress a variety of physiological and pathological 
immune responses through multiple mechanisms. Over the last decade, considerable progress 
has been made in elucidating molecular mechanisms underlying Treg development and 
differentiation. A key finding for understanding Treg development and function at the 
molecular level is the identification of Foxp3 as a hallmark of this population of suppressor 
cells. Since Foxp3 can confer Treg suppressive activity to conventional CD4
+
 T cells, 
Foxp3-dependent regulation and Foxp3 induction itself are expected to be appropriate targets 
for the manipulation of Treg activities. In addition, TCR signaling plays prominent roles for 
the differentiation and selection of Treg cells, hence the formation of their TCR repertoire. 
Impairment or augmentation of Foxp3-dependent regulation or TCR signaling can alter the 
balance between Treg and effector T cells, leading to impaired peripheral self-tolerance and 
immune homeostasis. Pharmacological treatments that aim to modulate the balance between 
Treg and effector T cells will provide the novel therapeutic strategies in the treatment of 
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Fig. 1. A possible mechanism of Foxp3-mediated Treg function. Upon TCR engagement with 
self-peptide/MHC ligands, transcriptional factors that bind to the promoter or enhancer region 
of the Foxp3 gene control Foxp3 expression. Foxp3-dependent transcriptional regulation also 
requires direct interaction with other transcription factors including NFAT, Runx1, RORt and 
Eos. These interactions are critical for Treg function and development.  
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